Testing a new radioactive drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have an advanced solid tumor that has spread to other parts of the body, ideally bladder cancer or breast cancer.
- You must be able to provide a tumor tissue sample (either from an old biopsy or a new one).
- Your daily activities should be mostly normal (ECOG score 0-1).
- Your blood counts, liver, and kidney function need to be within safe limits as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
Hear when a new Urothelial Carcinoma (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.